NUVL Logo

Nuvalent, Inc. (NUVL) 

NASDAQ
Market Cap
$6.75B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
637 of 774
Rank in Industry
348 of 433

Largest Insider Buys in Sector

NUVL Stock Price History Chart

NUVL Stock Performance

About Nuvalent, Inc.

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent …

Insider Activity of Nuvalent, Inc.

Over the last 12 months, insiders at Nuvalent, Inc. have bought $0 and sold $227.8M worth of Nuvalent, Inc. stock.

On average, over the past 5 years, insiders at Nuvalent, Inc. have bought $52.71M and sold $87.25M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 650,000 shares for transaction amount of $21.77M was made by Flynn James E (director) on 2022‑11‑03.

List of Insider Buy and Sell Transactions, Nuvalent, Inc.

2024-11-15SalePresident and CEO
27,000
0.0375%
$87.94$2.37M+6.73%
2024-11-01SaleChief Development Officer
5,000
0.0071%
$88.60$442,980+3.93%
2024-10-31SaleChief Financial Officer
10,000
0.0144%
$89.19$891,879+3.91%
2024-10-28Saledirector
2,000
0.0026%
$91.73$183,4680.00%
2024-10-22Sale* Director by deputization
1M
1.3662%
$97.75$97.75M0.00%
2024-10-15SalePresident and CEO
27,000
0.0392%
$102.28$2.76M-9.46%
2024-10-01SaleChief Development Officer
5,000
0.0072%
$101.74$508,718-7.38%
2024-09-30SaleChief Financial Officer
10,000
0.0143%
$101.06$1.01M-3.92%
2024-09-23Saledirector
2,000
0.0029%
$102.75$205,500-1.88%
2024-09-16SaleChief Scientific Officer
32,795
0.0446%
$98.92$3.24M-9.02%
2024-09-16SaleChief Legal Officer
8,000
0.0106%
$96.47$771,798-9.02%
2024-09-09SaleChief Legal Officer
3,000
0.0046%
$88.18$264,546+13.48%
2024-09-03SaleChief Development Officer
5,000
0.0078%
$84.43$422,146+18.48%
2024-08-30SaleChief Financial Officer
10,000
0.0153%
$84.23$842,349+14.25%
2024-08-26Saledirector
2,000
0.0031%
$84.46$168,914+12.50%
2024-08-23SaleChief Scientific Officer
10,500
0.0162%
$85.08$893,340+10.63%
2024-08-23SaleChief Legal Officer
11,000
0.0169%
$85.04$935,440+10.63%
2024-08-23Saledirector
3,334
0.0051%
$85.02$283,457+10.63%
2024-08-08SaleChief Legal Officer
3,000
0.0046%
$68.78$206,348+30.91%
2024-08-01SaleChief Development Officer
5,000
0.0078%
$77.22$386,125+19.29%

Insider Historical Profitability

10.04%
Flynn James E* Director by deputization
8670512
12.203%
$94.9331+13.74%
Hack Andrew A. F.director
2697267
3.7962%
$94.9321+4.5%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Deerfield Management$1.5B30.9719.99M0%+$03.66
Fidelity Investments$660.41M13.628.79M+0.8%+$5.24M0.04
Paradigm BioCapital Advisors LP$313.71M6.474.18M+8.29%+$24.02M11.38
The Vanguard Group$256.21M5.293.41M+2.16%+$5.42M0.01
Perceptive Advisors$209.01M4.312.78M-4.61%-$10.1M0.14
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.